Aim 1: Determine the sensitivity and specificity of tissue/serum sMIC in predicting PSA recurrence (BCR) and/or variant (NE-like) progressive PCa. These assays will be done by immunohistochemistry for tissues and ELISA for serum. Aim 2: Identify and evaluate clinically and biologically significant N-glycan panels and autoantibodies in tissue and serum associated with BCR and/or NE-like PCa. We will determine N-glycan panels in the same tissue/serum cohorts as in Aim 1 using MALDI imaging mass spectrometry. Aim 3: Validate prognostic capacity of the identified panel of serum biomarkers. We will perform this validation study in three independent cohorts of PCa patient samples with annotated prognostic information.
|Effective start/end date||9/30/17 → 9/29/21|
- U.S. Army Medical Research and Materiel Command (W81XWH-17-1-0642)
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.